Dow Inc. (DOW): what the price requires

At today's price, Dow Inc. (DOW) is priced for +6.1% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/DOW

Headline

FieldValue
TickerDOW
CompanyDow Inc.
Current price$30.17/sh
CompositionPackaging & Specialty Plastics 50% / Industrial Intermediates & Infrastructure 28% / Performance Materials & Coatings 20% / Corporate 2%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed2.3%
Operating margin (mid-cycle)3.6%
Margin compression implied-1.3pp
Trailing margin (depressed year)-3.4%
Implied growth6.1%
Multiple paid24x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 7.2% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~8.5pp.

Reconcile: at the x-ray's 9.3% required return this reads ~22.3%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history+0.90σ
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.51x2expensive
Earnings—0—
Relative1.53x2expensive
Growth7.00x1expensive

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.4%); the inversion above states its own rate.

Per-Model Detail (n=5)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$24.511.23xnoReference only (OCF-based, capex excluded): OCF $2.1B
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$81.800.37xyesP/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus
Simple DDMGrowth$4.317.00xyesDPS $1.40, g=-17.5% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$-17.26—noStage 1: -200% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$21.141.43xyesReference only (book value floor): BV/sh $21.14, ROE negative
Two-Stage Excess ReturnAsset$19.031.59xyesReference only (book value with convergence): BV/sh $21.14, ROE converges to ke
Discounted Future Market CapGrowth$14.832.03xnoRev $39.3B, growth -8% (input: historical growth; tapered), Terminal P/S: 0.5x / 0.6x / 0.6x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$11.202.69xyesEBITDA $2.84B × sector EV/EBITDA 8.0x
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$81.800.37xnoRevenue $39.33B × sector P/S 1.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$12.2b
Net debt / NOPAT (after-tax)10.63x
Net debt / operating income (pre-tax)8.40x
Interest coverage1.7x
Share count CAGR (buyback)-0.6%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 3.6%); the trailing year was depressed.

Bullet Takeaways

Dow is a commodity-chemicals maker in a deep down-cycle, with trailing operating income negative as a global oversupply pressures prices. The trajectory is turning, though: free cash flow swung from negative $581 million a year ago to positive $621 million in the first quarter on cost savings and working-capital discipline.

Management has acted on the weakness, cutting the dividend 50% to $1.40 a year, eliminating 4,500 roles, shutting European assets, and delaying its Path2Zero project, while a $3 billion infrastructure deal shored up the balance sheet.

At about $32 no valuation family fully reaches the price; it embeds a cyclical recovery. Net debt is about $12.2 billion with interest coverage near 1.6 times, so the recovery and the balance sheet are both load-bearing. Analysts average a target near $41.

Bull Case

The trajectory worth focusing on at Dow is cash flow, because in a commodity-chemicals down-cycle the question is not whether earnings are depressed, they are, but whether the company is generating cash and positioning for the upturn. On that measure the first quarter of 2026 marked a clear inflection. Free cash flow swung from negative $581 million a year earlier to positive $621 million, a $1.2 billion improvement delivered before polyethylene price increases even landed, driven by working-capital discipline and the first $193 million of realized cost savings. Operating EPS came in at a loss of $0.14, but that beat the consensus loss estimate, and revenue of $9.8 billion topped expectations, with the Packaging and Specialty Plastics segment posting 3% sequential volume growth.

Management has been aggressive in resizing the business for the trough. It cut the dividend 50% to a $1.40 annual rate to bring the payout within free cash flow, eliminated 4,500 roles, shut down higher-cost European assets, and delayed the multibillion-dollar Path2Zero decarbonization project in Alberta to conserve capital. The filings detail restructuring charges and asset write-downs tied to shutting certain assets as part of this program (Dow FY2025 10-K, accession 0001751788-26-000018). On top of the cost actions, a roughly $3 billion infrastructure stake sold to Macquarie and other asset sales have shored up the balance sheet. These are the moves a well-run cyclical makes at the bottom: cut cash outflows, raise liquidity, and wait.

The upside is leverage to the cycle turning. Dow is one of the largest and lowest-cost integrated chemical producers, with feedstock advantages in its US operations, so when polyethylene and broader chemical prices recover, the operating leverage is enormous: a thin-margin trough can become a wide-margin peak on the same volume. The price embeds a recovery already, but the stock at about $32 sits below the roughly $41 average analyst target and near the low end of where normalized earnings power could justify. The bull thesis is a self-helped, balance-sheet-shored, low-cost cyclical at the bottom of its cycle, with free cash flow already inflecting and a recovery in chemical prices the catalyst.

Bear Case

The fragile assumption baked into the price is that the chemical cycle recovers on schedule, and the bears have a specific reason to doubt the timing: the recent price tightness may be disruption-driven, and large new polyethylene capacity coming online in 2027 and 2028 could restore the oversupply that pushed Dow into losses in the first place. The whole bull case rests on prices recovering and holding, but in commodity chemicals, capacity additions have a way of arriving just as demand improves, capping the upturn. If the 2026 price increases prove temporary and the 2027-2028 supply wave lands, the normalized margins the price assumes do not materialize, and a stock priced for recovery has a long way to fall.

The second fragile assumption is that the balance sheet comfortably carries the company through the trough. Net debt is about $12.2 billion, leverage runs well above eight times trailing operating income, and interest coverage is only about 1.6 times, meaning operating profit barely covers interest. The dividend was already cut 50%, which is the clearest signal that the prior payout was unsustainable, and even at the reduced $1.40 the coverage depends on the free-cash-flow recovery continuing. The asset sales and the Path2Zero delay bought time and liquidity, but they are also the actions of a company under real financial pressure, and the filings document the restructuring charges and asset write-downs that come with shrinking to fit a weaker market (Dow FY2025 10-K, accession 0001751788-26-000018).

The valuation reflects an asset whose earnings power is genuinely uncertain. Trailing operating income is negative, so the earnings-power and cash-flow methods cannot produce meaningful values, and the reverse-DCF leans on a normalized margin assumption rather than current results. No valuation family fully reaches the price: it is rich on assets, earnings power, peers, and even forward growth on the trough numbers. The composite read is within range only because the normalization assumption does the work. The bet at $32 (June 27, 2026) is that the cycle turns, the price increases stick, and the balance sheet holds, three conditions that all depend on a recovery the bears think is premature, and the bear case is that a leveraged commodity producer with a freshly cut dividend is cheap because the recovery is neither certain nor durable.

Valuation

At about $32 the price inverts to roughly 8% operating-profit growth a year, with the solve built on a normalized operating margin of about 3.6% rather than today's negative trailing margin, because the trailing earnings are in a cyclical trough. The solve runs at a 7.3% cost of capital and is sensitive: each percentage point of cost of capital moves the implied growth by roughly 8.4 points, so the read is approximate and depends heavily on the normalization assumption.

The model X-ray is shaped by the down-cycle. The earnings-power, FCF-yield, and several relative methods cannot run because trailing operating income and free cash flow are negative. The asset-based book-value floors land near $19 to $21, just below the price, off a $21.14 book value. The relative methods that do run split widely, with EV/EBITDA near $11 on depressed EBITDA and the price-to-sales fallback near $82 on a large revenue line with no margin, the latter excluded because it ignores profitability. The dividend model lands low at about $4 because the payout was cut and the sustainable-growth input is negative.

The pattern is that no family fully reaches the price; it is rich on the trough numbers, and the valuation rests on a normalized-margin recovery the standard methods cannot confirm from current results. The book-value floor near $20 provides some downside support. The bet at $32 is that the chemical cycle recovers and normalized earnings power, not today's losses, define the business, while the methods grounded in current results place fair value at or below the price. The analyst average near $41 underwrites the recovery; the methods say the margin of comfort depends entirely on that recovery arriving.

Catalysts

First-quarter 2026 results were the most recent catalyst. Dow reported an operating loss of $0.14 a share, beating the consensus loss estimate, on revenue of $9.8 billion that topped expectations, with Packaging and Specialty Plastics up 3% sequentially in volume. The standout was free cash flow swinging from negative $581 million a year earlier to positive $621 million, helped by the first $193 million of cost savings. This followed the mid-2025 actions: a 50% dividend cut to $1.40 annually, 4,500 role eliminations, European asset shutdowns, a two-year delay of the Path2Zero project to 2029, and a roughly $3 billion infrastructure stake sold to Macquarie.

The forward catalysts center on the chemical cycle and the cost program. The key swing factor is whether polyethylene and broader chemical prices recover and hold, against the bear concern that 2027 and 2028 capacity additions restore oversupply. The watch items are the trajectory of chemical prices and Dow's realized margins, the continued ramp of cost savings toward the full program target, free-cash-flow generation and dividend coverage at the reduced payout, further asset sales or portfolio actions, and the eventual restart of Path2Zero spending. Analysts are split, roughly 8 buy, 10 hold, and 1 sell, with an average target near $41 and a wide range from the high $20s to the low $50s.

Peer Cohorts (Per Segment, With Filing Citations)

Packaging & Specialty Plastics (reported)

Industrial Intermediates & Infrastructure (reported)

Performance Materials & Coatings (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive DOW report on boothcheck